Company / Cash & Equivalents
Agilent Technologies Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.8B
FY2025
5-year range
$1.3B / $1.8B
FY2021-FY2025
Trend
+34.6%
vs FY2024
Sector context
#24 of 148
Health Care
What the data says
Agilent Technologies's cash & equivalents of $1.8B is higher than 84% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $1.3B in FY2024 to $2.7B in FY2018.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +5.3%. Top quartile in the Health Care sector.
Improved from $1.5B to $1.8B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- +5.3%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 148This company $1.8B Sector average $1.2B
▼
+52.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 34.6% year-over-year.
- Ranks #24 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2018.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +34.6% |
| FY2024 | $1.3B | -10.4% |
| FY2023 | $1.5B | +0.0% |
| FY2022 | $1.5B | +3.0% |
| FY2021 | $1.4B | +4.3% |
| FY2020 | $1.4B | +0.0% |
| FY2019 | $1.4B | -48.4% |
| FY2018 | $2.7B | +33.7% |
| FY2017 | $2.0B | -12.5% |
| FY2016 | $2.3B | +14.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026